Tisagenlecleucel (Kymriah)
CD19-directed CAR-T cell therapy for B-cell ALL, DLBCL, and follicular lymphoma.
What it targets
Targets CD19, a protein expressed on the surface of B-cell leukemia and lymphoma cells.
Who it may help
May benefit selected patients with CD19-positive B-cell ALL, DLBCL, or follicular lymphoma who have relapsed or become refractory to prior treatment.
Why testing matters
CD19 expression testing, bone marrow or biopsy, and full organ function panel required before CAR-T eligibility can be confirmed.
Which cancers does tisagenlecleucel treat?
Tisagenlecleucel is approved for selected CD19-positive B-cell malignancies in specific treatment settings. Below are the approved and considered uses.
| B-cell acute lymphoblastic leukemia (B-ALL) | For pediatric and young adult patients up to 25 years of age with refractory disease or second-or-later relapse. FDA and EMA approved. CD19 positivity required. |
| Diffuse large B-cell lymphoma (DLBCL) | For adults with relapsed or refractory DLBCL after two or more prior lines of systemic therapy, per EMA label. FDA label includes similar relapsed/refractory settings. |
| Follicular lymphoma | For adults with relapsed or refractory follicular lymphoma after two or more prior lines of systemic therapy. EMA approved. Specialist review required for eligibility. |
| Large B-cell lymphoma | Selected large B-cell lymphoma subtypes may be covered depending on local label interpretation and specialist review. Confirm with your treating oncologist. |
| Other CD19-positive cancers | Not routine use. May be considered in clinical trial settings for CD19-expressing B-cell malignancies not covered by current approvals. |
Who may be eligible for tisagenlecleucel?
Eligibility involves cancer type, CD19 status, prior treatment history, organ fitness, and certified center access. This is a specialist decision.
- Confirmed CD19-positive B-cell leukemia or lymphoma on biopsy or flow cytometry.
- Pediatric or young adult B-cell ALL that is refractory or has relapsed in the approved setting.
- Adult DLBCL or follicular lymphoma relapsed or refractory after two or more prior systemic therapies.
- Adequate heart, lung, liver, and kidney function to tolerate CAR-T therapy and potential CRS.
- No uncontrolled active infection or active inflammatory disorder at the time of infusion.
- Disease that can be managed safely during the CAR-T manufacturing period (3–4 weeks).
- Ability to remain near a qualified CAR-T center for at least 4 weeks after infusion.
- No prior treatment that would permanently impair T-cell collection or function.
- A treating CAR-T specialist who assesses expected benefit outweighs the risks for that patient.
How does tisagenlecleucel work?
- T-cell collection (leukapheresis)
- Cell engineering at the manufacturing facility
- Bridging therapy (if needed)
- Lymphodepleting chemotherapy
- Kymriah infusion
- Immune activation and monitoring
Tisagenlecleucel is a living therapy created from the patient's own immune cells. The process involves collection, engineering, expansion, and infusion — each step is essential.
Tests needed before tisagenlecleucel treatment
The following tests are typically required to confirm CAR-T eligibility, guide manufacturing, and establish a safety baseline.
| Biopsy / pathology confirmation | Histological or flow cytometric confirmation of B-cell leukemia or lymphoma diagnosis and CD19 expression. |
| CD19 expression testing | Flow cytometry or immunohistochemistry to confirm CD19 positivity — required for CAR-T eligibility. |
| Bone marrow biopsy | Required for B-ALL patients and selected lymphoma patients for disease staging and MRD assessment. |
| PET-CT / CT / MRI imaging | Staging and disease extent assessment — scan type depends on cancer type and treating center protocol. |
| CBC and differential | Full blood count to assess current counts, cytopenias, and baseline for monitoring. |
| Liver and kidney function tests | Organ function assessment for CAR-T eligibility and lymphodepleting chemotherapy safety. |
| Coagulation profile | Required given risk of coagulopathy during cytokine release syndrome. |
| Cardiac assessment (ECG and echo) | Baseline cardiac function required given risk of cardiac events with severe CRS. |
| Viral screening | Hepatitis B, hepatitis C, HIV, CMV, and other infections per center protocol. Active infection may delay or exclude CAR-T. |
| MRD testing (B-ALL) | Minimal residual disease testing by PCR or flow cytometry for B-ALL patients, where clinically appropriate. |
| Neurological baseline assessment | Baseline cognitive and neurological function to monitor for ICANS during post-infusion monitoring. |
| Pregnancy test | Required for patients of childbearing potential before lymphodepleting chemotherapy and CAR-T infusion. |
How is tisagenlecleucel given?
Tisagenlecleucel is given as a single intravenous infusion at a certified CAR-T treatment center. The infusion is part of a multi-week process that includes cell collection, manufacturing, and preparatory chemotherapy.
| Route of administration | Single intravenous infusion. Not a tablet, injection, or repeating chemotherapy cycle. |
| Dosage — B-cell ALL (pediatric/young adult) | Dose is weight-based and calculated per the approved prescribing information. Determined by the treating CAR-T team at the certified center. |
| Dosage — DLBCL and follicular lymphoma | Fixed dose as per the approved label for adult lymphoma patients. Determined by the certified CAR-T team. |
| Lymphodepleting chemotherapy | Fludarabine plus cyclophosphamide typically given 2–7 days before infusion to prepare the immune environment. |
| Infusion duration | The actual Kymriah infusion typically takes 30–60 minutes. Observation continues for several hours after infusion on day one. |
| Post-infusion monitoring period | Patients must remain within proximity to the certified CAR-T center for at least 4 weeks after infusion due to CRS and ICANS risk. |
| Treatment frequency | Single one-time infusion. There is no second infusion in the current approved protocol. |
| Setting | Must be administered at an authorized and certified CAR-T treatment center with 24-hour ICU capability. |
Clinical evidence and benefits of tisagenlecleucel
Tisagenlecleucel demonstrated clinically meaningful responses in pivotal trials across all three approved indications. Benefits are most pronounced in patients who achieve deep remission early.
| B-ALL remission — ELIANA trial | The pivotal ELIANA trial showed high overall remission rates in pediatric and young adult patients with relapsed or refractory B-cell ALL, including patients with prior transplant. |
| MRD-negative remission in B-ALL | A substantial proportion of responding B-ALL patients achieved undetectable minimal residual disease — a key marker associated with durable remission in leukemia. |
| DLBCL response — JULIET trial | The JULIET trial demonstrated meaningful response rates in adults with heavily pretreated relapsed or refractory DLBCL, including a proportion who achieved complete responses. |
| Durable responses in lymphoma | Complete responders in DLBCL and follicular lymphoma trials showed durable disease control over extended follow-up, with some patients remaining in remission without additional therapy. |
| One-time personalized therapy | As a single autologous infusion, tisagenlecleucel may provide long-lasting immune surveillance without the need for ongoing treatment cycles, which impacts quality of life for responders. |
| Option after multiple prior lines | Tisagenlecleucel provides a meaningful treatment option for patients who have exhausted standard chemotherapy, bispecific antibodies, or transplant pathways. |
Individual responses vary. Some patients achieve durable complete remission; others may relapse or not respond. Results represent published clinical trial data — outcomes in routine practice may differ.
Side effects of tisagenlecleucel
Tisagenlecleucel can cause serious and sometimes life-threatening immune-mediated side effects, particularly in the first weeks after infusion. Most patients experience some side effects; the CAR-T team is trained to manage them.
| Cytokine release syndrome (CRS) | The most common serious side effect. Can range from fever and chills to severe low blood pressure and oxygen problems. Most cases respond to tocilizumab or steroids. |
| Neurological toxicity (ICANS) | Immune effector cell-associated neurotoxicity syndrome — includes confusion, difficulty speaking, tremor, and in severe cases, seizures. Occurs with or without CRS. |
| Fever | Very common during CRS. Any fever after CAR-T infusion must be reported immediately to the CAR-T team. |
| Low blood pressure | Common in moderate to severe CRS. May require IV fluids, vasopressors, and ICU support in serious cases. |
| Low blood counts (cytopenias) | Low white cells, red cells, and platelets are expected after lymphodepleting chemotherapy and may persist for weeks. Infection risk is high during this period. |
| Infection | Immunosuppression from lymphodepleting chemotherapy and CAR-T therapy significantly increases infection risk. Antibacterial, antiviral, and antifungal prophylaxis is standard. |
| Low immunoglobulin levels (hypogammaglobulinemia) | B-cell aplasia from CD19-directed killing reduces antibody production. IVIG replacement may be needed, sometimes for months to years. |
| Fatigue | Very common during and after treatment. Can persist for weeks and affect daily function during the recovery period. |
| Nausea, diarrhea, poor appetite | Common during bridging therapy and lymphodepleting chemotherapy phase. Usually managed supportively. |
| Headache and confusion | May indicate early ICANS. Must be reported promptly to the CAR-T team, especially if progressive. |
| Secondary hematological malignancies | Rare but reported — FDA has communicated a safety signal regarding secondary T-cell malignancies following CAR-T therapies including Kymriah. Discuss this risk with your oncologist. |
Contact your CAR-T team immediately if you develop:
- Fever of 38°C (100.4°F) or higher after CAR-T infusion — may signal CRS onset.
- Breathing difficulty, low oxygen, or persistent chest tightness.
- Confusion, unusual drowsiness, or sudden difficulty speaking or writing.
- Tremor, seizure, or sudden loss of coordination.
- Severe dizziness, fainting, or very low blood pressure.
- Signs of serious infection: chills, rigors, rapid heart rate, or worsening weakness.
- Unusual bleeding, bruising, or signs of very low platelets.
Safety precautions before and during tisagenlecleucel treatment
Tell your entire treatment team — including the CAR-T center, your oncologist, and your GP — about all medical history, medications, supplements, and herbal products.
- Active or recent infection: CAR-T must not be given during uncontrolled active infection. Fully disclose any current or recurrent infections.
- Hepatitis B, hepatitis C, HIV, or tuberculosis: screening is mandatory. Active infection may require treatment before CAR-T eligibility can be confirmed.
- Prior CD19-directed therapy: prior treatment with anti-CD19 agents may have reduced CD19 expression and should be disclosed before eligibility testing.
- Prior stem cell transplant: disclose timing, type, and any graft-versus-host disease history. GVHD treatment may affect T-cell quality.
- Cardiac, hepatic, renal, or pulmonary disease: organ function is assessed before approval — significant impairment may affect eligibility or increase CRS risk.
- Neurological history (seizures, stroke, encephalopathy): baseline assessment required; prior neurological conditions increase ICANS monitoring intensity.
- Autoimmune disease: active autoimmune conditions may be worsened by CAR-T-mediated immune activation.
- Pregnancy or breastfeeding: CAR-T therapy is not recommended. Effective contraception is required before, during, and for a period after treatment.
- Live vaccines: generally avoided for a prolonged period around CAR-T therapy. Discuss specific vaccine timing with your CAR-T team.
- Corticosteroids and immunosuppressants: systemic steroids can impair CAR-T cell expansion. Disclose all immunosuppressive medications.
Tisagenlecleucel combination and sequencing strategies
Tisagenlecleucel is given as a standalone infusion after lymphodepleting chemotherapy. However, the broader treatment pathway often involves bridging therapy, side-effect management agents, and post-CAR-T options.
| Lymphodepleting chemotherapy (mandatory) | Fludarabine plus cyclophosphamide is given before all CAR-T infusions to create space for CAR-T cell expansion. This is a standard preparatory step, not a combination in the traditional sense. |
| Bridging therapy (pre-CAR-T) | Temporary leukemia or lymphoma therapy given during the manufacturing wait period — may include blinatumomab, inotuzumab, steroids, or other agents depending on disease type. |
| Tocilizumab and steroids (CRS management) | Tocilizumab (IL-6 inhibitor) is the first-line agent for moderate-to-severe CRS. Corticosteroids are used for ICANS management and severe CRS. |
| Allogeneic stem cell transplant (post-CAR-T) | Selected B-ALL patients in deep remission after CAR-T may be considered for consolidative allogeneic transplant. Specialist discussion required. |
| Bispecific antibodies and ADCs (post-CAR-T failure) | Blinatumomab, inotuzumab, loncastuximab, or axicabtagene ciloleucel may be considered if disease relapses after tisagenlecleucel failure, depending on CD19 status. |
| Clinical trial combinations | Trials are studying tisagenlecleucel in combination or sequence with checkpoint inhibitors, novel CD19-targeting agents, and CAR-T manufacturing enhancements. |
If tisagenlecleucel stops working
Relapse after CAR-T therapy can occur through loss of the CD19 target, poor CAR-T cell persistence, or selection of CD19-negative clones. Understanding the mechanism guides next steps.
| CD19 antigen loss | The most common resistance mechanism — cancer cells lose CD19 expression under selective pressure from CAR-T therapy, making the cells invisible to the CAR. Confirmed by repeat biopsy and flow cytometry. |
| Poor CAR-T cell persistence | CAR-T cells may not persist in sufficient numbers to maintain long-term remission. Factors include T-cell exhaustion, immunosuppressive tumor microenvironment, and prior treatment history. |
| CD19-negative relapse | Relapse with CD19-negative disease requires switching to CD22-directed therapy (inotuzumab), bispecific antibodies, or other non-CD19 approaches. |
| Next-line options after CAR-T failure | Depending on CD19 status, disease type, and fitness: blinatumomab, inotuzumab, axicabtagene ciloleucel (second CAR-T), allogeneic transplant, or clinical trial enrollment. |
| Repeat biopsy and MRD testing | Essential at relapse to confirm disease re-emergence, characterize CD19 status, and rule out therapy-related changes before deciding on next treatment. |
Cost of tisagenlecleucel by country
Tisagenlecleucel is among the highest-cost oncology therapies globally. Total costs extend beyond the drug itself to include manufacturing, hospitalization, supportive care, and monitoring.
| USA | List price for the drug alone has been reported in the hundreds of thousands of dollars per infusion. Total care costs are higher. Novartis outcomes-based payment programs available at select centers. Insurance coverage varies widely. |
| UK / Europe | Kymriah is EMA approved. NHS England provides conditional reimbursement under managed access agreements for approved indications. Coverage and access vary by country within Europe. |
| India | Kymriah is not domestically approved or commercially available in India as of 2026. Patients seeking CAR-T therapy in India may access domestic CD19 CAR-T products in clinical trials or seek international referral pathways. |
| China | China has approved domestic CD19 CAR-T products (e.g., axicabtagene ciloleucel equivalents and domestically manufactured therapies). Costs are substantially lower than Western markets. CancerFax can help coordinate access. |
| Singapore / South Korea / Israel | Selected centers offer Kymriah access in these countries under approved or compassionate-use pathways. Costs are high; insurance and hospital-specific reimbursement applies. |
| Total treatment cost components | Includes: cell collection, manufacturing, hospital admission, lymphodepleting chemotherapy, ICU readiness, supportive medicines, monitoring, and travel and accommodation for international patients. |
Availability of tisagenlecleucel globally
Kymriah is commercially available in countries where FDA and EMA approval applies. In other markets, access depends on domestic approvals, clinical trial availability, or international referral pathways.
USA
FDA approved for B-cell ALL (up to 25 years), DLBCL, and follicular lymphoma. Available at certified CAR-T centers across the country. Patient assistance programs exist for eligible patients through Novartis.
Europe (EMA)
EMA approved for B-cell ALL, DLBCL, and follicular lymphoma. Access through certified centers in EU member states. NHS England provides managed access for covered indications in the UK.
India
Kymriah is not domestically approved in India as of mid-2026. Access may be possible via international referral or select domestic CD19 CAR-T clinical trials. CancerFax can help assess current options.
China
China has approved domestic CD19 CAR-T products and has a growing network of certified centers. Tisagenlecleucel (Kymriah) is not separately approved in China, but equivalent therapies are available at lower cost.
Singapore / South Korea
Select certified centers offer CAR-T therapy under approved or compassionate access pathways. Access for international patients is possible with referral through CancerFax.
Other markets
Access in the Middle East, Southeast Asia, and other regions varies by country. Clinical trial enrollment or international referral to FDA/EMA-approved centers is the most common pathway.
Tisagenlecleucel in clinical trials
Research continues to expand the use of tisagenlecleucel and next-generation CD19 CAR-T therapies, focusing on earlier treatment lines, new manufacturing approaches, and combination strategies.
| Earlier-line B-cell ALL | Trials exploring tisagenlecleucel in first relapse of high-risk pediatric B-ALL to determine if earlier use improves long-term outcomes compared to standard salvage and transplant. |
| Earlier-line DLBCL | Studies evaluating CD19 CAR-T therapies including tisagenlecleucel in second-line DLBCL settings, potentially before autologous stem cell transplant eligibility is assessed. |
| Follicular lymphoma — extended follow-up | Long-term follow-up studies of the ELARA trial cohort to characterize durability of responses in follicular lymphoma patients treated with tisagenlecleucel. |
| CAR-T after prior CD19 therapy | Trials investigating CAR-T strategies for patients who have already received anti-CD19 agents such as blinatumomab or axicabtagene ciloleucel, including dual-targeting approaches. |
| Manufacturing innovations | Next-generation CAR-T manufacturing trials studying faster turnaround times, point-of-care manufacturing, and T-cell engineering improvements to enhance persistence and reduce exhaustion. |
| Combination with checkpoint inhibitors | Early-phase trials studying co-administration of PD-1 or PD-L1 checkpoint inhibitors with CAR-T therapy to improve expansion and durability in lymphoma settings. |
Your treatment journey with tisagenlecleucel
Diagnosis and pathology confirmation
CAR-T specialist consultation
Eligibility workup and center preparation
T-cell collection (leukapheresis)
Bridging therapy and manufacturing wait
Lymphodepleting chemotherapy
Kymriah infusion
Post-infusion monitoring (weeks 1–4)
Response assessment
Long-term follow-up
Questions to ask your oncologist about tisagenlecleucel
- Is my leukemia or lymphoma CD19-positive, and does that make me eligible for CAR-T?
- Which specific approval — B-ALL, DLBCL, or follicular lymphoma — applies to my case?
- Is my disease stable enough to survive the CAR-T manufacturing wait?
- What is my expected risk of cytokine release syndrome, and how will it be managed?
- What neurological side effects should my caregiver watch for after infusion?
- How long will I need to stay near the CAR-T center, and what does monitoring look like?
- What is the full expected cost, and what financial assistance is available?
- What are my options if tisagenlecleucel does not work or if cancer comes back?
- Should I consider a second opinion before proceeding with CAR-T therapy?
How CancerFax supports tisagenlecleucel patients
CancerFax helps patients and families navigate every phase of the CAR-T journey — from initial eligibility questions to international access coordination and post-CAR-T planning.
| Medical report review | Upload your biopsy, CD19 flow cytometry, bone marrow, or imaging reports — our oncology team reviews them and explains your eligibility for CAR-T therapy. |
| CAR-T specialist connection | We connect patients with hematologists, pediatric oncologists, and CAR-T specialists in India, China, Singapore, South Korea, and internationally. |
| Second opinion coordination | For patients uncertain about CAR-T eligibility, center selection, or post-CAR-T options, CancerFax arranges second opinions from CAR-T expert centers. |
| China CAR-T access guidance | China has approved domestic CD19 CAR-T therapies at substantially lower costs. CancerFax coordinates full access for eligible international patients, including hospital coordination and logistics. |
| International access and logistics | For patients outside the USA or Europe, CancerFax manages the full coordination — hospital identification, medical record transfer, travel, accommodation, and interpreter support. |
| Post-CAR-T follow-up planning | We connect patients with oncologists who can manage long-term CAR-T follow-up — including monitoring for late cytopenias, immunoglobulin replacement, infection risk, and relapse surveillance. |
Frequently asked questions about tisagenlecleucel
Common questions from patients and caregivers about Kymriah CAR-T therapy
Tisagenlecleucel (Kymriah) is a CAR-T cell therapy — a one-time, personalized treatment made from the patient's own immune cells. Unlike chemotherapy, which kills both cancerous and healthy cells, tisagenlecleucel is engineered to recognize and attack only CD19-positive cancer cells. It is a living therapy, meaning the modified cells can persist and continue to surveil the body after infusion.
Tisagenlecleucel is approved for pediatric and young adult patients (up to 25 years of age) with refractory or second-or-later relapsed B-cell acute lymphoblastic leukemia, and for adults with relapsed or refractory DLBCL or follicular lymphoma after two or more prior systemic therapies. Eligibility depends on CD19-positive disease, organ fitness, no active infections, and access to a certified CAR-T center. Your oncologist will assess your specific suitability.
The process typically takes 3 to 6 weeks from T-cell collection to infusion. After leukapheresis (cell collection), the cells are sent to the manufacturer for engineering and expansion, which takes 3–4 weeks. Bridging therapy may be given during this wait. After infusion, patients must remain near the CAR-T center for monitoring for at least 4 weeks due to the risk of cytokine release syndrome and neurologic toxicity.
Cytokine release syndrome, or CRS, occurs when the infused CAR-T cells become very active and release large amounts of inflammatory proteins called cytokines. It can cause fever, low blood pressure, low oxygen levels, and rapid heartbeat, and in severe cases requires ICU-level care. Most cases are manageable with tocilizumab and corticosteroids at a certified CAR-T centre. The Yescarta prescribing information includes a boxed warning for CRS because it can be life-threatening if not promptly treated.
Kymriah (the brand name for tisagenlecleucel) is FDA and EMA approved. Availability in India and China varies — India does not yet have a domestic commercial approval for Kymriah, but some centers offer access through international referral pathways or clinical trials. China has its own CD19 CAR-T products approved domestically. CancerFax can help assess your current access options based on your country, diagnosis, and treatment history.
If leukemia or lymphoma relapses after tisagenlecleucel, a biopsy and CD19 testing are usually performed first — CD19 loss is a known resistance mechanism. Depending on results, the oncologist may recommend bispecific antibodies (such as blinatumomab), antibody-drug conjugates (inotuzumab), targeted therapy, allogeneic stem cell transplant, or clinical trial enrollment. A second specialist opinion is strongly advisable after CAR-T failure.
Prior allogeneic stem cell transplant is not an automatic exclusion for tisagenlecleucel, but it complicates eligibility. The treating oncologist and CAR-T center will assess graft-versus-host disease status, immune recovery, organ function, and time since transplant. Clinical trial evidence includes patients with prior transplants. Disclosure of all prior therapies is essential during the CAR-T eligibility workup.
Tisagenlecleucel is one of the most expensive oncology treatments globally. The drug's list price in the US has been reported at several hundred thousand dollars per infusion, with total care costs higher. Novartis has patient assistance and outcomes-based payment programs in some markets. In countries without approval, access through clinical trials or international referral may carry different cost structures. CancerFax can help explore financial pathways and cost navigation for your country.